Coping With Somatic Comorbidities: Striving for Complete Recovery
By Christer Allgulander, MD, and Siegfried Kasper, MD
Optimizing Treatment Outcomes for Patients With Depression and Generalized Anxiety Disorder
By Michael E. Thase, MD, and Madhukar Trivedi, MD
Long-Term Treatment Strategies in Anxiety Disorders
By Christer Allgulander, MD, Robert M. A. Hirschfeld, MD, and David J. Nutt, MD, PhD
Generalized Anxiety Disorder: Raising the Expectations of Treatment
By Christer Allgulander, MD, and David V. Sheehan, MD, MBA
New Developments in the Neurobiological Basis of Anxiety Disorders
By Jack M. Gorman, MD, Robert M. A. Hirschfeld, MD, and Philip T. Ninan, MD
Long-Term Treatment Strategies in Affective Disorders
By Martin B. Keller, MD
Recent Advances in the Neurobiology of Depression
By Charles B. Nemeroff, MD, PhD
Remission: Today’s Target in the Treatment of Mood and Anxiety Disorders
Comparing the Methods Used to Compare Antidepressants
By Michael E. Thase, MD
Neuropharmacology of Paroxetine
By Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD
Intermittent Fluoxetine Dosing in the Treatment of Women With Premenstrual Dysphoria
By Meir Steiner, MD, PhD, FRCPC, Marilyn Korzekwa, MD, FRCPC, John Lamont, MD, MSc, FRCSC, and Annette Wilkins, BA
Pharmacokinetics, Drug Interactions, and Tolerability of Paroxetine and Paroxetine CR
By Lindsay DeVane, PharmD
Efficacy and Tolerability of Controlled-Release Paroxetine
By Robert N. Golden, MD
A Discussion on the Methodologies Used to Evaluate Antidepressants
MODERATOR: Jan A. Fawcett, MD
DISCUSSANTS: Norman Sussman, MD Jeffrey H. Newcorn, MD
Risperidone: Review of Its Therapeutic Utility in Depression
By Joyce E. Myers, MD, and Michael E. Thase, MD
A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors
By Mikael Landén, MD, PhD, and Michael E. Thase, MD